On June 2, 2018 Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that its preliminary data from its ongoing Phase 1/2 ICONIC trial, an adaptive design, open-label trial evaluating JTX-2011 alone and in combination with nivolumab in patients with advanced solid tumors (Press release, Jounce Therapeutics, JUN 2, 2018, View Source;p=RssLanding&cat=news&id=2352867 [SID1234527089]). Safety and preliminary clinical activity data from all evaluable patients across multiple tumor types will be presented in an oral presentation today, Saturday, June 2, 2018 at the 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, IL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are encouraged by the early signal of clinical activity in heavily pre-treated patients, accompanied by an ICOS pharmacodynamic biomarker. We believe that this biomarker may help guide further development of JTX-2011," said Elizabeth Trehu, M.D., chief medical officer of Jounce Therapeutics. "Importantly, JTX-2011 continues to be safe and well-tolerated both as a single agent and in combination with nivolumab. We look forward to continuing clinical evaluation of JTX-2011, including initiation of new combination dose escalation cohorts within the ICONIC trial of JTX-2011."

The ICONIC study (ICOS AgONist Antibody for Immunotherapy in Cancer Patients) is an open label, dose escalation and expansion clinical study of JTX-2011 alone and in combination with a fixed dose of nivolumab in patients with advanced solid tumors. Patients were heavily pre-treated with approximately 65 percent having received 3 or more prior therapies (i.e. 4th line or greater); approximately 65 percent discontinued during the first three cycles. The adaptive design includes Parts A and B (Phase 1), and C and D (Phase 2), with the Phase 2 cohorts enriched for high ICOS expression. The data presented today include preliminary efficacy data from all evaluable patients as of an April 4, 2018 cut-off date. The Phase 1 portion of ICONIC was a dose escalation study to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). The patients in Phase 2 received JTX-2011 0.3 mg/kg every 3 weeks alone or in combination with nivolumab 240 mg every 3 weeks. Preliminary efficacy evaluation included tumor reductions and RECIST (response evaluation criteria in solid tumors) responses.

Summary of JTX-2011 ICONIC Data

Safety

JTX-2011 was well tolerated alone and in combination with nivolumab 240 mg every 3 weeks. The overall safety profile observed was consistent with previously reported data from the Phase 1 portion of the ICONIC trial.
Clinical Activity

Gastric Cancer

A RECIST partial response (PR) with JTX-2011 monotherapy was observed in 1 of 8 Phase 2 patients (7 PD-1 inhibitor naïve, including PR), ongoing at 8.5+ months.
Two RECIST PRs with JTX-2011 plus nivolumab were observed in 1 of 4 Phase 1 patients (all PD-1 inhibitor naïve) and 1 of 28 Phase 2 patients (22 PD-1 inhibitor naïve, including PR), ongoing at 11+ and 4+ months, respectively.
Disease control(1) was observed in 10 of 28 and tumor reductions were observed in 8 of 28 Phase 2 patients treated with JTX-2011 plus nivolumab, including both PD-1 inhibitor naïve and PD-1 inhibitor failures.
Triple Negative Breast Cancer (TNBC)

A RECIST PR with JTX-2011 plus nivolumab was observed in 1 of 17 Phase 2 patients (16 PD-1 inhibitor naïve, including PR), ongoing at 4+ months.
Disease control was observed in 3 of 17 and tumor reductions were observed in 2 of 17 Phase 2 patients treated with JTX-2011 plus nivolumab, all PD-1 inhibitor naïve.
Head and neck squamous cell cancer (HNSCC) PD-1 inhibitor failures

Disease control was observed in 2 of 16 and tumor reductions were observed in 1 of 16 Phase 2 patients treated with JTX-2011 plus nivolumab, all PD-1 inhibitor failures, of whom over 50 percent were refractory(2) to prior PD-1 inhibitors.
Non-small cell lung cancer (NSCLC) PD-1 inhibitor failures

Disease control was observed in 7 of 12 and tumor reductions were observed in 4 of 12 Phase 2 patients treated with JTX-2011 plus nivolumab, all PD-1 inhibitor failures.
(1) Disease control= confirmed PR + SD ≥ 9 weeks
(2) Refractory= best response to prior PD-1 inhibitor was progressive disease

Biomarkers

In a preliminary analysis of evaluable fresh pre-treatment biopsies, rates of disease control and tumor reduction appear higher in subjects with high ICOS scores.
An ICOS pharmacodynamic biomarker (emergence of peripheral blood ICOS high CD4 T cell population) appears to associate with anti-tumor activity.
Present in 7 of 7 subjects with target lesion PRs
Absent in 10 of 10 subjects with progressive disease
Based on preliminary signals of clinical activity associated with an ICOS pharmacodynamic biomarker, Jounce is advancing clinical evaluation of JTX-2011. The next steps for the program include continuing to evaluate the ongoing data and the initiation of two new dose escalation cohorts within the ICONIC trial of JTX-2011, one in combination with ipilimumab and one in combination with pembrolizumab. The new ipilimumab combination cohort may enable Jounce to explore a new combination mechanism that is supported by clinical and pre-clinical research. Exploration with pembrolizumab at its approved q3w dose and schedule may allow the Company to evaluate JTX-2011in combination with a PD-1 inhibitor in earlier lines of therapy.

"We look forward to evaluating the new additional combinations with JTX-2011. From our founding science, the platform we have built, and the team we have in place, we believe we are well positioned to optimize the development of JTX-2011," said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. "We are grateful to all of the patients who have participated in our trial, their families, our investigators and their study teams. This was a complex biomarker heavy trial that was well executed by the Jounce team."

ICONIC Enrollment Status
Phase 1 has completed enrollment and Phase 2 is nearing completion of enrollment. Given the pace of enrollment of the combination cohorts in gastric cancer, TNBC, HNSCC, NSCLC and the overall quantity of the data collected, Jounce made the decision to stop recruitment of other solid tumors and of the more slowly enrolling monotherapy and melanoma combination cohorts.

Jounce Therapeutics to Host Event and Webcast
Jounce Therapeutics will host an investor and analyst event beginning at 6:30 p.m. CT (7:30 p.m. ET) with a live webcasted presentation beginning at 7:00 p.m. CT (8:00 p.m. ET), on Monday, June 4, 2018. To access the live webcast, please visit the "Events & Presentations" page in the Investors and Media section of the company’s website at www.jouncetx.com. The webcast will be archived and made available for replay on the company’s website approximately two hours after the call and will be available for 30 days thereafter.

About JTX-2011
Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS, the Inducible T cell CO­Stimulator, a protein on the surface of certain T cells. Preclinical data support that JTX-2011 may have a dual mechanism of action that stimulates anti-tumor T effector cells, and also reduces the immunosuppressive T regulatory cells in the tumor microenvironment. The company is developing JTX-2011 to treat solid tumors as a single agent and in combination with other therapies.

On June 2, 2018 Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, reported that results from a multicenter Phase 2 study of tesetaxel, administered orally as a single agent to patients with HER2 negative, hormone receptor (HR) positive, metastatic breast cancer (MBC), were presented at the 2018 ASCO (Free ASCO Whitepaper) Annual Meeting in Chicago, Illinois(Poster Board #123; Abstract #1042) (Press release, Odonate Therapeutics, JUN 2, 2018, View Source [SID1234527106]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this Phase 2 study (Study TOB203), 38 patients with HER2 negative, HR positive, MBC received tesetaxel orally as a single agent once every 3 weeks (Q3W) at a starting dose of 27 mg/m2. Eighty-seven percent (87%) had visceral disease, 74% previously received at least one endocrine therapy, 68% previously received neoadjuvant or adjuvant chemotherapy and 53% previously received a taxane-containing regimen. Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with confirmation no less than 4 weeks after initial response was the primary endpoint.

In all 38 patients, the confirmed response rate was 45%. The confirmed response rate was consistent across subgroups. Forty-four percent (44%) of patients who did not previously receive a taxane-containing regimen achieved a confirmed response, compared to 45% of patients who previously received a taxane-containing regimen. Median duration of response was 10.9 months, and median progression-free survival was 5.4 months.

Neutropenia was the most common Grade ≥3 adverse event and occurred in 25% of the 24 patients who were not dose-escalated beyond the 27 mg/m2 starting dose (the dose selected for CONTESSA, our ongoing Phase 3 study (Poster Board #184a; Abstract #TPS1106); in these patients, febrile neutropenia occurred in 1 patient (4%) and Grade ≥3 neuropathy occurred in 1 patient (4%). There were no hypersensitivity reactions or drug-related deaths, and the rate of Grade 2 alopecia (hair loss) was 18%.

"Despite recent advances in the treatment of advanced breast cancer, there remains a significant need for new therapies that allow patients to maintain a better quality of life," said Joyce O’Shaughnessy, M.D., Celebrating Women Chair in Breast Cancer Research, Baylor University Medical Center, Texas Oncology and Chair, Breast Cancer Research, US Oncology.

"Tesetaxel’s significant single-agent activity, once-every-three-week oral dosing and low rates of neuropathy and hair loss could make this investigational agent a unique treatment option for patients, if approved," said Andrew Seidman, M.D., Attending Physician and Associate Chair, Academic Administration, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC) and Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College. "We look forward to further characterizing tesetaxel’s therapeutic profile in CONTESSA, an ongoing Phase 3 study."

About Tesetaxel

Tesetaxel is an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; no history of hypersensitivity (allergic) reactions; and significant activity against chemotherapy-resistant tumors. More than 500 patients have been treated with tesetaxel in clinical studies. In patients with metastatic breast cancer, tesetaxel was shown to have significant, single-agent antitumor activity in two, multicenter, Phase 2 studies.

About CONTESSA

CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel, an investigational, orally administered taxane, in patients with locally advanced or metastatic breast cancer (LA/MBC). CONTESSA is comparing tesetaxel dosed orally at 27 mg/m2 on the first day of a 21-day cycle plus a reduced dose of capecitabine (1,650 mg/m2/day dosed orally on days 1-14 of a 21-day cycle) to the approved dose of capecitabine alone (2,500 mg/m2/day dosed orally on days 1-14 of a 21-day cycle) in approximately 600 patients randomized 1:1 with HER2 negative, hormone receptor (HR) positive LA/MBC previously treated with a taxane in the neoadjuvant or adjuvant setting. Capecitabine is an oral chemotherapy agent that is considered a standard-of-care treatment in LA/MBC. Where indicated, patients must have received endocrine therapy with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor. The primary endpoint is progression-free survival (PFS) assessed by an Independent Radiologic Review Committee (IRC). CONTESSA’s secondary efficacy endpoints are overall survival, objective response rate (ORR) assessed by IRC and disease control rate assessed by IRC. To learn more, please visit www.contessastudy.com.

On June 1, 2018 Roche (SIX: RO, ROG; OTCQX: RHHBY) reported that data from across its genitourinary (GU) and gastrointestinal (GI) cancer immunotherapy development programme will be presented during the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting from 1-5 June in Chicago, IL, United States (Press release, Hoffmann-La Roche, JUN 1, 2018, View Source [SID1234527020]). Data to be presented at ASCO (Free ASCO Whitepaper) 2018 demonstrate the potential of the combination of TECENTRIQ (atezolizumab) and Avastin (bevacizumab) in first-line advanced or metastatic renal cell carcinoma (mRCC) and hepatocellular carcinoma (mHCC), as well as show initial data for TECENTRIQ monotherapy as a neoadjuvant treatment in early stage urothelial carcinoma (UC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to present positive Patient-Reported Outcomes data from the Phase III IMmotion151 study, which demonstrate the quality of life benefits that TECENTRIQ and Avastin potentially bring to people living with advanced kidney cancer," said Sandra Horning, M.D., Chief Medical Officer and Head of Global Product Development. "We will also present promising early data for TECENTRIQ and Avastin in advanced or metastatic liver cancer, where there is a significant need for new therapies. Data from these two studies provide further evidence to support the potential of this unique combination across multiple settings."

Patient-Reported Outcome (PRO) collected in the Phase III IMmotion151 study investigating the combination of TECENTRIQ and Avastin as a first-line treatment for mRCC, compared with a current standard of care sunitinib, were evaluated in the overall study population and show:

Patients receiving the combination reported a better health-related quality of life (HRQol) overall when compared with sunitinib. HRQol evaluates the overall impact of disease and treatment on patient’s quality of life in terms of disease related symptoms, treatment side effects and function/well-being
Patients receiving the combination reported lower impact of symptoms on day-to-day life, when compared with patients receiving sunitinib
The combination of TECENTRIQ and Avastin markedly increased the time before symptoms meaningfully impacted day-to-day life compared to sunitinib (median time to deterioration: 11.3 vs 4.3 months; HR=0.56; 95% CI: 0.46, 0.68)
Patients receiving the combination had milder and more stable symptom severity overall and a clinically meaningful reduction in the five most severe disease symptoms
Patients completed questionnaires on Days 1 and 22 of each 6-week cycle, at the end of treatment
Earlier this year, Roche announced that IMmotion151 met its co-primary endpoint of investigator-assessed progression-free survival (PFS) when comparing the TECENTRIQ and Avastin combination with sunitinib for people whose disease expressed the PD-L1 (programmed death-ligand 1) protein. The safety profile was consistent with previously reported data, with a discontinuation of the combination regimen only occurring in 5% of the patients and a lower rate of Grade 3-4 treatment-related adverse events with the TECENTRIQ and Avastin combination (40%) than with sunitinib alone (54%). 16% of patients required use of systemic steroids within 30 days of the onset of an immune-related AE.

Further data for TECENTRIQ and Avastin will be presented from an ongoing Phase Ib study evaluating the combination as a first-line treatment in untreated advanced, unresectable or metastatic HCC. In the safety evaluable population (n=43), 28% patients (n=12) experienced Grade 3-4 treatment-related adverse events and no treatment-related Grade 5 adverse events were observed. No new safety signals were identified beyond the established safety profiles for the individual medicines. After a median follow-up of 10.3 months, responses (investigator assessed per RECIST v1.1) were seen in 14 (61%) of 23 efficacy evaluable patients and regardless of disease etiology (cause), region (Asia or US), baseline alpha-fetoprotein levels or spread of tumour beyond the liver. Assessment by independent review facility (IRF) assessed per RECIST v1.1 revealed a response rate of 65% (15 out of 23 patients). Median progression free survival (PFS), duration of response (DOR), time to progression (TTP) and overall survival (OS) have not yet been reached after a median follow-up of 10.3 months; results will be presented at a future medical congress when updated data from an expanded cohort are available. A larger randomised Phase III study in untreated locally advanced or metastatic HCC, IMbrave150, evaluating the combination of TECENTRIQ and Avastin versus the standard of care sorafenib, is underway and recruiting patients.

In early stage bladder cancer, results from an interim analysis of a Phase II investigator-initiated study (ABACUS) evaluating neoadjuvant TECENTRIQ monotherapy in 68 evaluable patients with muscle invasive disease will also be presented. Topline results demonstrated a clinically meaningful pathological complete response (pCR) rate of 18 / 62 (29%). Of the pCR patients, 17% had pT3/4 disease at baseline. Treatment-related Grade 3-4 adverse events occurred in 12% of patients while Grade 3-4 surgical complications occurred in 31% of patients. The trial aims to test the efficacy of preoperative TECENTRIQ and includes extensive biomarker work on samples from these patients.

The results of the three studies will be presented at the 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting on Sunday 3 June 2018.

About the IMmotion151 study
IMmotion151 is a Phase III multicentre, randomised, open-label study to evaluate the efficacy and safety of TECENTRIQ and Avastin versus sunitinib in people with inoperable, locally advanced or metastatic renal cell carcinoma (RCC) who have not received prior systemic active or experimental therapy. It enrolled 915 people globally who were randomised 1:1 to receive TECENTRIQ and Avastin, or sunitinib alone.

People in the TECENTRIQ and Avastin arm received TECENTRIQ at a fixed dose of 1200 milligrams (mg) and Avastin at a dose of 15 milligrams per kilogram (mg/kg) via intravenous (IV) infusion every 3 weeks until loss of clinical benefit or unacceptable toxicity. People in the sunitinib arm received sunitinib 50 mg orally, once daily for 4 weeks followed by 2 weeks rest until loss of clinical benefit or unacceptable toxicity.

The co-primary endpoints were PFS, as determined by the investigator using Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in people whose tumours expressed PD-L1 (expression ≥1 percent on immune cells [IC]), and OS in the overall study population (intention-to-treat, ITT). PD-L1 expression was prospectively assessed using an immunohistochemistry (IHC) test (SP142) developed by Roche Tissue Diagnostics. Secondary endpoints included OS in people whose tumours expressed PD-L1, PFS as determined by an Independent Review Facility (IRF) according to RECIST v1.1, investigator-assessed objective response rate (ORR) and duration of response (DOR), change from baseline in symptom interference and symptom severity as determined by M.D. Anderson Symptom Inventory (MDASI), and change from baseline in health-related quality of life as determined by European Quality of Life 5-Dimension (EQ-5D) Scores. PROs were evaluated as secondary and exploratory endpoints to document patient perspective on overall clinical benefit for each treatment.

About the Phase Ib study in HCC (NCT02715531)
This Phase Ib study evaluates the safety and clinical activity of the combination of TECENTRIQ and Avastin in people with untreated advanced, unresectable or metastatic HCC. Patients received TECENTRIQ (1200 mg) + Avastin (15 mg/kg) IV every 3 weeks until loss of clinical benefit or unacceptable toxicity. The primary objective was to assess the safety and tolerability as well as the efficacy of the combination. The primary efficacy endpoint is investigator-assessed objective response rate (ORR). Secondary efficacy endpoints include progression-free survival (PFS), duration of response (DOR) and time to progression (TTP) per RECIST v1.1; as well as overall survival (OS).

About IMbrave150
IMbrave150 is a Phase III, multicentre, randomised open-label study randomising approximately 480 patients with untreated advanced, unresectable or metastatic hepatocellular carcinoma 2:1 to receive TECENTRIQ in combination with Avastin or sorafenib. TECENTRIQ will be administered by IV, 1200mg on day 1 of each 21 day cycle and Avastin will be administered by IV, 15mg/kg on day 1 of each 21 day cycle. Sorafenib will be administered by mouth, 400mg twice per day, on days 1-21 of each 21 day cycle. Patients will receive the combination and the control arm until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Co-primary endpoints are overall survival and investigator-assessed objective response rate. Secondary endpoints include progression free survival (PFS), time to progression (TTP), duration of response (DOR) and independent review facility (IRF) assessed responses.

About the ABACUS study
ABACUS is an investigator-initiated, open-label, international, multicentre, phase II trial for patients with histologically confirmed (T2-T4a) transitional cell carcinoma of the bladder. The trial aims to test the efficacy of preoperative TECENTRIQ and includes extensive biomarker work on samples from these patients. Patients received two 3-weekly cycles of TECENTRIQ prior to cystectomy. Following cystectomy, patients were followed up for safety, survival, and disease data. Co-primary endpoints are (1) efficacy of atezolizumab prior to cystectomy assessed as pathological complete response rate and (2) immune parameters. Secondary endpoints include safety and efficacy based on anti-tumour effect by radiological response.

About TECENTRIQ (atezolizumab)
TECENTRIQ is a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, TECENTRIQ may enable the activation of T cells. TECENTRIQ has the potential to be used as a foundational combination partner with cancer immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers.

TECENTRIQ is already approved in the European Union, United States and more than 70 countries for people with previously treated metastatic NSCLC and for people with locally advanced or metastatic urothelial cancer (mUC) who are not eligible for cisplatin chemotherapy, or who have had disease progression during or following platinum-containing therapy.

About the TECENTRIQ (atezolizumab) and Avastin (bevacizumab) combination
There is a strong scientific rationale to support combining TECENTRIQ and Avastin. The TECENTRIQ and Avastin regimen may enhance the potential of the immune system to combat a broad range of cancers. Avastin, in addition to its established anti-angiogenic effects, may further enhance TECENTRIQ’s ability to restore anti-cancer immunity, by inhibiting VEGF-related immunosuppression, promoting T-cell tumour infiltration and enabling priming and activation of T-cell responses against tumour antigens.

About renal cell carcinoma
Kidney cancer remains one of the most common cancers in the world, accounting for over 140,000 deaths worldwide each year,1 with renal cell carcinoma (RCC) accounting for approximately 90% of all cases.2 Over 300,000 people are diagnosed with RCC every year and currently only about 1 in 10 people are alive beyond 5 years following diagnosis of metastatic disease.3

RCC occurs when abnormal cells develop in the tissue of the kidneys, specifically in the small tubes (also known as tubules) where our blood is filtered.4 Typically, RCC is a single tumour in one kidney but, in rare cases, there can be multiple tumours, which can occur in one or both kidneys.5

Despite recent progress in the field of kidney cancer, treatment options for people with the disease remains limited.

About hepatocellular carcinoma
HCC is the most common primary malignancy of the liver and has a very high fatality rate.6 Globally, it’s the fifth most common cancer in men and the seventh most common cancer among women, with over half a million new cases diagnosed annually.6 HCC develops predominantly in those patients with cirrhosis due to chronic hepatitis B or C,6 and typically presents at an advanced stage where there are limited treatment options.7

About urothelial carcinoma
Bladder cancer is the ninth most common cancer worldwide, with 430,000 new cases diagnosed in 2012, and it results in approximately 165,000 deaths globally each year. Men are three times more likely to suffer from bladder cancer, compared with women,8 and the disease is three times more common in developed countries than in less developed countries.9 There are three types of bladder cancer: transitional cell carcinoma (which begins in cells in the innermost tissue layer), squamous cell carcinoma (which begins in squamous cells) and adenocarcinoma (which begins in glandular cells in the lining of the bladder). Most cancers that form in the bladder are transitional cell carcinomas.10

On June 1, 2018 CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, reported that it will host a conference call and live webcast on Monday, June 4th at 5:00 p.m. CT/ 6:00 p.m. ET to discuss presentations of preliminary clinical results from PROCLAIM-072, an ongoing Phase 1/2 trial evaluating CX-072, a Probody therapeutic targeting PD-L1, at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper). Conference call and webcast details are as follows (Press release, CytomX Therapeutics, JUN 1, 2018, View Source [SID1234527038]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date and Time:

Monday, June 4, 2018
5:00 p.m. Central Time/ 6:00 p.m. Eastern Time
Audio Conference Call:

U.S. Toll Free Dial-in Number: (877) 809-6037
International Dial-in Number: (615) 247-0221
Conference ID: 4294667
Live Webcast:

Access the Events and Presentations Section of CytomX’s Investor Relations section at View Source
Access the website 15 minutes prior to the start of the call to download and install any necessary audio software with slides
Replay:

A replay of the webcast will be archived and available on CytomX’s website for three months following the event.

On June 1, 2018, bluebird bio, Inc. ("bluebird") presented the investor presentation(Presentation, bluebird bio, JUN 1, 2018, View Source [SID1234527246]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!